🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Survival Analysis in patiEnts With Bad Prognosis Epithelial Ovarian CArcinoma

Recruitingn/aAges 18 Years - anyFemaleFondazione Policlinico Universitario Agostino Gem…
NCT07540403 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Ovarian carcinoma is the most lethal gynecological malignancy. Epithelial ovarian carcinoma is the gynecological malignancy with the highest mortality rate. The prognosis of patients with recurrent disease is highly heterogeneous and is typically poor in cases of ovarian carcinoma with a progression-free survival (PFS) ≤ 6 months, for which therapeutic options are limited. However, it has been shown that patients with a PFS ≤ 6 months may not respond effectively to further treatments, whereas, conversely, patients with a PFS \> 6 months could still benefit from them. The classification of patients with recurrent disease has undergone continuous evolution over time. Essential factors to consider include patient characteristics, disease stage, and the precise genetic and molecular profile of the tumor. This study aims to evaluate survival in patients experiencing recurrence of epithelial

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
1. INCLUSION CRITERIA * Patients diagnosed with histologically confirmed epithelial ovarian carcinoma, fallopian tube carcinoma, or primary peritoneal carcinoma with a PFS ≤6 months. * Age ≥18 years. * Any FIGO (Federation of Gynecology and Obstetrics) stage at diagnosis. * Signed informed consent for the use of personal data for research purposes. * ECOG performance status ≤2. 2. EXCLUSION CRITERIA * Age \<18 years. * Patients with non-epithelial ovarian carcinoma. * Patients with a PFS \>6 months.
💊

What it tests

  • Not listed
📍

Where

1 site
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Rome, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy